NextCure, Inc.
NextCure, Inc. (NXTC) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · NXTC · as of Jun 9, 2026
Key Statistics
Explore NextCure, Inc. Data
nxtc stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 84.6%
The NXTC analyst consensus is Buy, based on ratings from 13 Wall Street analysts over the past 3 months. The average 12-month price target is $15.00, representing +437.63% upside from the current price of $2.79.
Competitors & Peers
nxtc competitorsNXTC
ANTX
BOLD
INTS
ITRM
JSPRStock Performance
Full HistoryAbout NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related condi…
what is nextcure, inc. · nxtc stock overview · nextcure, inc. company profile · who is nextcure, inc. ceo · nxtc NASDAQ · nextcure, inc. headquarters · nextcure, inc. business segments
About Stock Overview & Key Data
NextCure, Inc. (NXTC) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 9, 2019. As of the latest trading session, NXTC stock price is $2.79, with a market capitalization of $7.5M. The stock has returned -55.99% over the past 12 months and -80.34% year-to-date.
According to 13 Wall Street analysts, the consensus rating for NextCure, Inc. stock is Buy, with an average 12-month price target of $15.00. In fiscal year 2025, NextCure, Inc. reported revenue of — and net income of -$55.8M. For detailed data — including NextCure, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, NextCure, Inc. (NXTC) stock price is $2.79. The stock is traded on NASDAQ under the ticker symbol NXTC. The 52-week range is $2.65 – $15.74.